Richard Levy

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Francisco Cervantes, Giovanni Barosi, Viktoriya Stalbovskaya, 2012, The New England journal of medicine.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Ayalew Tefferi, Z. Estrov, H. Kantarjian, 2010, The New England journal of medicine.